长效奥曲肽对肝纤维化大鼠IL-6、IL-8的影响

Observation of effects of long-acting octreotide(Sandostatin LAR) on IL-6,IL-8 in rats with liver fibrosis

目的观察长效奥曲肽对四氯化碳(CCl4)诱发大鼠肝纤维化白细胞介素-6(interleukin-6,IL-6)、白细胞介素-8(in-terleukin-8,IL-8)的影响。方法SD大鼠40只,随机分为正常对照组(n=8)、肝纤维化组(n=16)和长效奥曲肽组(n=16)。以40%CCl4皮下注射(3mL/kg)建立大鼠肝纤维化模型,长效奥曲肽组同时给予长效奥曲肽(0.8mg/kg),每4周肌肉注射1次。8周后观察肝脏组织形态学改变、用酶联免疫吸附法(ELISA)检测血清IL-6和IL-8。结果正常对照组大鼠肝脏大体形态和组织学无异常改变;肝纤维化门脉高压组及长效奥曲肽组大鼠肝脏组织形态学表现为肝纤维化改变,但后者的病理损害指标显著轻于前者(P<0.05);正常对照组血清IL-6、IL-8含量分别为(175.28±31.15)pg/mL、(81.51±16.48)μg/mL,肝纤维化组血清IL-6、IL-8含量分别为(313.27±52.79)pg/mL、(213.15±31.16)μg/mL,而长效奥曲肽组分别为(265.13±46.57)pg/mL、(185.16±32.56)μg/mL,肝纤维化组和长效奥曲肽组血清IL-6、IL-8均显著高于正常对照组,但后者两项指标显著低于前者(P<0.05)。结论长效奥曲肽能减轻大鼠肝纤维化程度及降低血清IL-6和IL-8水平。

Objective To observe the effects of long-acting release octreotide（Sandostatin LAR） on IL-6,IL-8 in rats with liver fibrosis by CCl4. Methods Forty SD rats were assigned randomly into 3 groups,i, e. normal control group（8 cases） ,fibrosis group （16 cases） and long-acting octreotide group（16 cases）. Apart from the normal control group, the rats in the remaining two groups were subcutaneously injected with 40 % CCl4 （3mL/kg）for induction of fibrosis. The rats in the long acting octreotide group were treated additionally with tandostatin LAR（0.8mg/kg） intramuscularly once every four weeks. After 8 weeks, the rats were measured before pathological evaluation including macroscopic features of the liver,and plasma IL-6 as well as IL-8 was determined with ELISA. Results There were neither macroscopic nor microscopic abnormalities demonstrated in the liver in the normal control group. In the latter two groups, the liver got hard, blunting and nodosity-like, but significantly lessened injuries,including fatty degeneration and necrosis, fibroplasias, deformed structures and formation of pseudo-lobule shown in long acting oetreotide group, compared with fibrosis group. Plasma IL-6 and IL-8 in the normal control group were （175.28 ± 31. 15）pg/mL, （81.51 ± 16.48） μg/mL,respeetively. The two parameters in the fibrosis group were （313.27±52.79）pg/mL, （213.15±31. 16）μg/mL,and （265. 13±46.57）pg/mL, （185.16±32.56）μg/mL respectively in the long acting octrcotide group,both significantly higher than those in the controls（P〈0.05）. However, the parameters detected in the long acting octreotide group were significantly lower than those in the fibrosis group（P〈0.05）. Conclusion Sandostatin LAR may reduce liver fibrosis,and decrease plasma IL-6 and IL-8.